Apelin and ACE2 in cardiovascular disease

Current Opinion in Investigational Drugs

Volumn 11, Issue 3, 2010, Pages 273-282

  Kalea, A Z ^a   Batlle, D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

ACE2; Apelin; APJ; Cardiovascular disease; Endothelium; Receptor; Vascular tone

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANTIHYPERTENSIVE AGENT; APELIN; APELIN RECEPTOR;

ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; ENZYME REGULATION; GENE EXPRESSION; HEART FAILURE; NONHUMAN; PROTEIN HYDROLYSIS; PROTEIN INTERACTION; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PEPTIDYL-DIPEPTIDASE A;

EID: 77649110591     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Zhong J-C, Yu 1. X-Y, Huang Y, Yung L-M, Lau C-W, Lin S-G: Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res (2007) 74(3):388-395.
2. Katugampola S, Maguire J, Matthewson S, Davenport A: [125I]-(Pyr1)apelin- 13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol (2001) 132(6):1255-1260.
3. Szokodi I, Tavi P, Földes G, Voutilainen-Myllylä S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysä J, Tóth M, Ruskoaho H: Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res (2002) 91(5): 434-440.
4. Tatemoto K, Takayama K, Zou M-X, Kumaki I, Zhang W, Kumano K, Fujimiya M: The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept (2001) 99(2-3):87-92.
5. Lee D, Cheng R, Nguyen T, Fan T, Kariyawasam A, Liu Y, Osmond D, George S, O'Dowd B: Characterization of apelin, the ligand for the APJ receptor. J Neurochem (2000) 74(1):34-41.
6. Cheng X, Cheng XS, Pang CC: Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol (2003) 470(3):171-175.
7. Földes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, Mäyränpää M, Sármán B, Seres L, Skoumal R, Lakó-Futó Z et al: Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun (2003) 308(3): 480-485.
8. Atluri P, Morine K, Liao G, Panlilio C, Berry M, Hsu V, Hiesinger W, Cohen J, Joseph Woo Y: Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett (2007) 12(1):127-138.
9. Malyszko J, Pawlak K, Mysliwiec M: Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci (2008) 53(1): 32-36.
10. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, Zheng L, Leeper NJ, Pearl NE, Patterson AJ, Anderson JP et al: Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest (2008) 118(10):3343-3354.
11. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S et al: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem (2002) 277(17):14838-14843.
12. Masri B, Knibiehler B, Audigier Y: Apelin signalling: A promising pathway from cloning to pharmacology. Cell Signal (2005) 17(4):415-426.
13. Sorli SC, van den Berghe L, Masri B, Knibiehler B, Audigier Y: Therapeutic potential of interfering with apelin signalling. Drug Discov Today (2006) 11(23-24):1100-1106.
14. Kleinz MJ, Davenport AP: Emerging roles of apelin in biology and medicine. Pharmacol Ther (2005) 107(2):198-211.
15. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou M-X, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T et al: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun (1998) 251(2):471-476.
16. Lee DK, Lanca AJ, Cheng R, Nguyen T, Ji XD, Gobeil F Jr, Chemtob S, George SR, O'Dowd BF: Agonist-independent nuclear localization of the apelin, angiotensin AT1, and bradykinin B2 receptors. J Biol Chem (2004) 279(9):7901-7908.
17. Choe H, Farzan M, Konkel M, Martin K, Sun Y, Marcon L, Cayabyab M, Berman M, Dorf ME, Gerard N, Gerard C et al: The orphan seven-transmembrane receptor APJ supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. J Virol (1998) 72(7):6113-6118.
18. O'Dowd BF, Heiber M, Chan A, Heng HHQ, Tsui L-C, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T: A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene (1993) 136 (1-2):355-360.
19. Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O'Dowd BF: Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology (2005) 146(1):231-236.
20. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, Nishizawa N, Kitada C, Onda H, Nishimura O, Fujino M: Molecular properties of apelin: Tissue distribution and receptor binding. Biochim Biophys Acta (2001) 1538(2-3):162-171.
21. Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, Kitada C, Nishizawa N, Murosaki S, Kurokawa T, Onda H et al: Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta (1999) 1452(1):25-35.
22. Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A, Castan-Laurell I, Tack I, Knibiehler B, Carpéné C, Audigier Y et al: Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology (2005) 146(4):1764-1771.
23. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP: [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: Vasoactive mechanisms and inotropic action in disease. Hypertension (2009) 54(3):598-604.
24. Kleinz MJ, Skepper JN, Davenport AP: Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept (2005) 126(3):233-240.
25. Kleinz MJ, Davenport AP: Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept (2004) 118(3):119-125.
26. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, Kitada C, Honda S, Kurokawa T, Onda H, Nishimura O et al: Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem (2000) 275(28):21061-21067.
27. Medhurst A, Jennings C, Robbins M, Davis R, Ellis C, Winborn K, Lawrie K, Hervieu G, Bolaky J, Herrity N, Murdock P et al: Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem (2003) 84(5):1162-1172.
28. O'Carroll A-M, Selby TL, Palkovits M, Lolait SJ: Distribution of mRNA encoding B78/Apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta (2000) 1492(1): 72-80.
29. Hashimoto T, Kihara M, Ishida J, Imai N, Yoshida S, Toya Y, Fukamizu A, Kitamura H, Umemura S: Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2006) 26(6):1267-1272.
30. Saint-Geniez M, Masri B, Malecaze F, Knibiehler B, Audigier Y: Expression of the murine Msr/Apj receptor and its ligand apelin is upregulated during formation of the retinal vessels. Mech Dev (2002) 110(1-2):183-186.
31. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, Deng A, Eichhorn J, Mahajan R, Agrawal R, Greve J et al: The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res (2005) 65(1):73-82.
32. Sheikh AY, Chun HJ, Glassford AJ, Kundu RK, Kutschka I, Ardigo D, Hendry SL, Wagner RA, Chen MM, Ali ZA, Yue P et al: In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol (2008) 294(1):H88-H98.
33. Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan B, Ferrario CM, Penninger JM, Batlle D: Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: Prevention of angiotensin II-dependent hypertension. Hypertension (2010) 55(1):90-98.
34. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Batlle D: ACE and ACE2 activity in diabetic mice. Diabetes (2006) 55(7):2132-2139.
35. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H: Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol (2004) 203(2):631-637.
36. Crackower M, Sarao R, Oudit G, Yagil C, Kozieradzki I, Scanga S, Oliveira-dos-Santos A, da Costa J, Zhang L, Pei Y, Scholey J et al: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 417(6891):822-828.
37. Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D: Localization of ACE2 in the renal vasculature: Amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol (2009) 296(2):F398-F405.
38. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE et al: A novel angiotensin-converting enzymerelated carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res (2000) 87(5):E1-E9.
39. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D: Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes. J Am Soc Nephrol (2006) 17(11): 3067-3075.
40. Masri B, Lahlou H, Mazarguil H, Knibiehler B, Audigier Y: Apelin (65-77) activates extracellular signal-regulated kinases via a PTX-sensitive G protein. Biochem Biophys Res Commun (2002) 290(1):539-545.
41. Masri B, Morin N, Cornu M, Knibiehler B, Audigier Y: Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J (2004) 18(15):1909-1911.
42. Masri B, Morin N, Pedebernade L, Knibiehler B, Audigier Y: The apelin receptor is coupled to Gi1 or Gi2 protein and is differentially desensitized by apelin fragments. J Biol Chem (2006) 281(27):18317-18326.
43. Bai B, Tang J, Liu H, Chen J, Li Y, Song W: Apelin-13 induces ERK1/2 but not p38 MAPK activation through coupling of the human apelin receptor to the Gi2 pathway. Acta Biochim Biophys Sin (2008) 40(4):311-318.
44. Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, Yu F, Duan XH, Tang CS, Qi YF: Apelin activates l-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides (2007) 28(10):2023-2029.
45. Hus-Citharel A, Bouby N, Frugiere A, Bodineau L, Gasc J-M, Llorens-Cortes C: Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int (2008) 74(4):486-494.
46. Zhong J-C, Huang Y, Yung L-M, Lau C-W, Leung F-P, Wong W-T, Lin S-G, Yu X-Y: The novel peptide apelin regulates intrarenal artery tone in diabetic mice. Regul Pept (2007) 144(1-3): 109-114.
47. Japp AG, Cruden NL, Amer DAB, Li VKY, Goudie EB, Johnston NR, Sharma S, Neilson I, Webb DJ, Megson IL, Flapan AD et al: Vascular effects of apelin in vivo in man. J Am Coll Cardiol (2008) 52(11):908-913.
48. Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, Woo YJ: Apelin has in vivo inotropic effects on normal and failing hearts. Circulation (2004) 110(suppl II):II-187-II-193.
49. Kagiyama S, Fukuhara M, Matsumura K, Lin Y, Fujii K, Iida M: Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept (2005) 125(1-3):55-59.
50. Zhang Q, Yao F, Raizada MK, O'Rourke ST, Sun C: Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res (2009) 104(12):1421-1428.
51. Gurzu B, Cristian Petrescu B, Costuleanu M, Petrescu G: Interactions between apelin and angiotensin II on rat portal vein. J Renin Angiotensin Aldosterone Syst (2006) 7(4): 212-216.
52. Goazigo AR-L, Morinville A, Burlet A, Llorens-Cortes C, Beaudet A: Dehydration-induced cross-regulation of apelin and vasopressin immunoreactivity levels in magnocellular hypothalamic neurons. Endocrinology (2004) 145(9):4392-4400.
53. Qadri F, Culman J, Veltmar A, Maas K, Rascher W, Unger T: Angiotensin II-induced vasopressin release is mediated through α-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus. J Pharmacol Exp Ther (1993) 267(2): 567-574.
54. Reaux A, De Mota N, Skultetyova I, Lenkei Z, El Messari SG, K, Corvol P, Palkovits M, Llorens-Cortès C: Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem (2001) 77(4):1085-1096.
55. De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C, Kordon C, Vaudry H, Moos Fo, Llorens-Cortes C: Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci USA (2004) 101(28):10464-10469.
56. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, Sugaya T, Matsuzaki H, Yamamoto R, Shiota N, Okunishi H et al: Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem (2004) 279(25):26274-26279.
57. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y, Leschnik M, Leibbrandt A, Markovic M, Schwaighofer J, Beetz N et al: Impaired heart contractility in apelin gene-deficient mice associated with aging and pressure overload. Circ Res (2007) 101(4):e32-e42.
58. Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA: Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol (2006) 296(1): 177-189.
59. Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, Yano T, Fujii R, Takakura N: Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J (2008) 27(3):522-534.
60. Kunduzova O, Alet N, Delesque-Touchard N, Millet L, Castan- Laurell I, Muller C, Dray C, Schaeffer P, Herault JP, Savi P, Bono F et al: Apelin/APJ signaling system: A potential link between adipose tissue and endothelial angiogenic processes. FASEB J (2008) 22(12):4146-4153.
61. Kälin RE, Kretz MP, Meyer AM, Kispert A, Heppner FL, Brändli AW: Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol (2007) 305(2):599-614.
62. Iwanaga Y, Kihara Y, Takenaka H, Kita T: Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol (2006) 41(5):798-806.
63. Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, Ben-Dor A, Fenster B, Yang E, King JY, Fowler M et al: Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation (2003) 108(12):1432-1439.
64. Chong K, Gardner R, Morton J, Ashley E, McDonagh T: Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail (2006) 8(4):355-360.
65. Weir RAP, Chong KS, Dalzell JR, Petrie CJ, Murphy CA, Steedman T, Mark PB, McDonagh TA, Dargie HJ, McMurray JJV: Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail (2009) 11(6):551-558.
66. Goulter A, Goddard M, Allen J, Clark K: ACE2 gene expression is up-regulated in the human failing heart. BMC Medicine (2004) 2:19-26.
67. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC: Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: Evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation (2003) 108(14):1707-1712.
68. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM: Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension (2004) 43(5):970-976.
69. Ferrario CM, Trask AJ, Jessup JA: Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol (2005) 289(6):H2281-H2290.
70. Falcao-Pires I, Goncalves N, Henriques-Coelho T, Moreira-Goncalves D, Roncon-Albuquerque R Jr, Leite-Moreira AF: Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol (2009) 296(6):H2007-H2014.
71. Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, Friis-Hansen L: Apelin: A new plasma marker of cardiopulmonary disease. Regul Pept (2006) 133(1-3):134-138.
72. Andersen CU, Markvardsen LH, Hilberg O, Simonsen U: Pulmonary apelin levels and effects in rats with hypoxic pulmonary hypertension. Respir Med (2009) 103(11):1663-1671.
73. Hashimoto T, Kihara M, Imai N, Yoshida S, Shimoyamada H, Yasuzaki H, Ishida J, Toya Y, Kiuchi Y, Hirawa N, Tamura K et al: Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol (2007) 171(5): 1705-1712.
74. Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A, Bingol N, Kilic S, Bingol S, Erikci S: Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes (2007) 115(7):428-432.
75. Li Z, Bai Y, Hu J: Reduced apelin levels in stable angina. Intern Med (2008) 47(22):1951-1955.
76. Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwiec M: Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc (2008) 40(10):3466-3469.
77. Sluimer JC, Gasc JM, Hamming I, van Goor H, Michaud A, van den Akker LH, Jütten B, Cleutjens J, Bijnens AP, Corvol P, Daemen MJ et al: Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol (2008) 215(3):273-279.
78. Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, Levitt KS, Oudit GY, Al-Omran M, Stewart DJ, Slutsky AS et al: Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol (2008) 295(4):H1377-H1384.
79. Ronkainen V-P, Ronkainen JJ, Hanninen SL, Leskinen H, Ruas JL, Pereira T, Poellinger L, Vuolteenaho O, Tavi P: Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J (2007) 21(8):1821-1830.
80. Sowter HM RP, Watson P, Greenberg AH, Harris AL: HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res (2001) 61(18): 6669-6673.
81. Kietzmann T, Roth U, Jungermann K: Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood (1999) 94(12):4177-4185.
82. Kralisch S, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M: Growth hormone induces apelin mRNA expression and secretion in mouse 3T3-L1 adipocytes. Regul Pept (2007) 139(1-3):84-89.
83. Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D, Ayav A, Ziegler O, Carpene C, Saulnier-Blache J-S, Valet P et al: TNFα up-regulates apelin expression in human and mouse adipose tissue. FASEB J (2006) 20(9):1528-1530.
84. Zhang J, Ren CX, Qi YF, Lou LX, Chen L, Zhang LK, Wang X, Tang C: Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci (2006) 79(12):1153-1159.
85. Hamada J, Kimura J, Ishida J, Kohda T, Morishita S, Ichihara S, Fukamizu A: Evaluation of novel cyclic analogues of apelin. Int J Mol Med (2008) 22(4):547-552.
86. El Messari S, Iturrioz X, Fassot C, De Mota N, Roesch D, Llorens-Cortes C: Functional dissociation of apelin receptor signaling and endocytosis: Implications for the effects of apelin on arterial blood pressure. J Neurochem (2004) 90(6):1290-1301.
87. Iturrioz X, Alvear-Perez R, De Mota N, Franchet C, Guillier F, Leroux V, Dabire H, Le Jouan M, Chabane H, Gerbier R, Bonnet D et al: Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J (2009):doi:10.1096/fj.09-140715.
88. Simpkin J, Yellon D, Davidson S, Lim S, Wynne A, Smith C: Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemiareperfusion injury. Basic Res Cardiol (2007) 102(6):518-528.